In non-TTP TMA patients, the measurement of ADAMTS13 would allow not only to consider a different diagnosis and treatment, but also to interrupt PEX when started, considering that this therapy is not free from adverse effects, some of which can be life threatening. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.